NVAX
NOVAVAX INC
+0.94 (+10.00%)10.29USD4.6M成交股數1.7B市值–本益比(近四季)4.1股價營收比-76.3%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 56.7M-76% | 140M-79% | 147M+74% | 70.4M-83% | 239M+155% | 667M+129% | 84.5M-55% | 415M-2% | 93.9M | 291M | 187M | 424M |
| 營業成本 | 14.2M | 30.7M | 22.1M | 21.5M | 15.3M | 14.1M | 60.6M | 46.2M | 59.2M | 155M | 98.9M | 55.8M |
| 毛利 | 42.5M-81% | 109M-83% | 125M+423% | 48.9M-87% | 224M+546% | 653M+379% | 23.9M-73% | 369M+0% | 34.6M | 136M | 88.1M | 369M |
| 毛利率 | 74.9% | 78.0% | 85.0% | 69.5% | 93.6% | 97.9% | 28.3% | 88.9% | 36.9% | 46.8% | 47.1% | 86.9% |
| 研發費用 | 70.7M | 95.5M | 75.9M | 98.3M | 79.2M | 88.9M | 87.2M | 107M | 92.7M | 165M | 106M | 219M |
| 銷售管理費用 | 26.7M | 28.8M | 34.1M | 31.7M | 43.6M | 48.1M | 70.7M | 101M | 86.8M | 155M | 107M | 93.7M |
| 營業利益 | −54.9M-154% | −15.4M-103% | 14.2M-111% | −178M-211% | 101M-170% | 516M-381% | −134M+7% | 161M+190% | −145M | −184M | −126M | 55.5M |
| 營業利益率 | -96.8% | -11.1% | 9.7% | -252.7% | 42.2% | 77.3% | -158.6% | 38.7% | -154.3% | -63.0% | -67.2% | 13.1% |
| 稅後淨利 | −53.4M-150% | −9.5M-102% | 17.5M-114% | −202M-225% | 107M-172% | 519M-391% | −121M-7% | 162M+180% | −148M | −178M | −131M | 58.0M |
| 淨利率 | -94.2% | -6.8% | 11.9% | -287.3% | 44.5% | 77.8% | -143.5% | 39.1% | -157.2% | -61.2% | -69.9% | 13.7% |
| 稀釋 EPS | -0.32-152% | -0.06-102% | 0.28-137% | -1.25-226% | 0.62-159% | 2.93-322% | -0.76-40% | 0.99+71% | -1.05 | -1.32 | -1.26 | 0.58 |
| 稀釋股數 | 165M | 163M | 173M | 162M | 177M | 178M | 160M | 166M | 140M | 101M | 103M | 104M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 191M | 228M | 241M | 268M | 254M | 263M | 574M | 680M | 481M | 569M | 651M | 506M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | 10.0M | 11.5M | 11.5M | 13.5M | 10.2M | 10.3M | 8.6M | 9.2M | 15.8M | 41.7M | 69.6M | 23.5M |
| 總資產 | 956M | 1.0B | 1.2B | 1.2B | 1.3B | 1.3B | 1.7B | 1.8B | 1.4B | 1.8B | 1.7B | 1.7B |
| 有息負債 | 291M | 291M | 244M | – | – | – | – | – | – | – | – | – |
| 總負債 | 1.1B | 1.2B | 1.3B | 1.3B | 1.3B | 1.4B | 2.2B | 2.3B | 2.2B | 2.5B | 2.3B | 2.4B |
| 股東權益 | −191M | −145M | −128M | −157M | 37.6M | −75.6M | −526M | −432M | −867M | −717M | −678M | −755M |
| 負債比 | 120.0% | 113.9% | 110.9% | 113.3% | 97.2% | 105.9% | 130.7% | 123.7% | 164.1% | 139.9% | 140.9% | 144.8% |
| 淨現金(現金 − 有息負債) | −100M | −62.7M | −3.6M | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −32.4M-83% | – | – | – | −186M | – | – | −83.6M | – | – | – |
| 資本支出 | – | 1.3M | – | – | – | 1.6M | – | – | 6.9M | – | – | – |
| 自由現金流 | – | −33.7M-82% | – | – | – | −187M | – | – | −90.4M | – | – | – |
| 折舊攤銷 | – | 3.1M | – | – | – | 8.3M | – | – | 12.1M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -24.2% | – | – | – | -28.1% | – | – | -96.4% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 1.1B
| Reportable | 1.1B | 100.0% | +64.7% |
|---|
產品／服務2025 年度 · 1.1B
| Nuvaxovid Sales | 625M | 55.6% | +228.7% |
|---|---|---|---|
| Licensing Royalties And Other | 438M | 39.0% | -6.5% |
| Supply Sales | 59.9M | 5.3% | +160.4% |
| 產品 小計 | 685M | 61.0% | +221.3% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 1.1B | +64.7% | 440M | 39.2% | 2.58 | −250M |
| FY2024 | 682M | -30.7% | −187M | -27.5% | -1.23 | −100M |
| FY2023 | 984M | -50.4% | −545M | -55.4% | -5.41 | −768M |
| FY2022 | 2.0B | +72.9% | −658M | -33.2% | -8.42 | −505M |
| FY2021 | 1.1B | +141.0% | −1.7B | -152.1% | -23.44 | 265M |
| FY2020 | 476M | +2448.5% | −418M | -87.9% | -7.27 | −97.2M |
| FY2019 | 18.7M | -45.6% | −133M | -711.0% | -5.51 | −138M |
| FY2018 | 34.3M | – | −185M | -538.8% | -9.99 | −186M |